Decode News AI
简体繁體

CG Oncology Bladder Cancer Drug Cuts Recurrence Risk 68%

2026-11-16 15:01 EST · AI-compiled · 248 words · about 1 min · Views …
Photo: AI-generated illustration

DALLAS - CG Oncology reported on Nov.

367-Patient Trial Shows Clean Safety Profile

The study enrolled 367 patients across roughly 90 U.S. and Canadian sites, recording a 0.32 hazard ratio at a 17-month median follow-up as of Oct. 26.

No Grade 3 or higher treatment-related adverse events or treatment-related discontinuations occurred. 13, as the company noted about 50,000 U.S. patients in this group lack an FDA-approved post-surgery option.

Dual FDA Filings Targeted for 2027

Detailed topline findings will be presented at the Society of Urologic Oncology Annual Meeting on Dec. 2. CG Oncology also expects to finish a broadened initial FDA filing for BCG-unresponsive bladder cancer by the end of March 2027, with all supporting manufacturing steps completed.

Sources

Found a factual error or typo? Tell us

Follow Decode News AI on Telegram

Live updates: every new story is pushed the moment it publishes — dozens a day, no digest delay.

@decodenewsai · Subscribe now

Free · unsubscribe anytime

Comments